Latest News - Abbott Laboratories
Top Corporates Hub
Abbott Laboratories
Abbott Laboratories (ABT) Posted Higher Sensitivity Data For Colorectal Cancer Recurrence Detection
24.10.2026 10:13
Abbott Laboratories (NYSE:ABT) reported new Beta-CORRECT study data on its Oncodetect test at ESMO 2026. The Beta-CORRECT trial showed a significant sensitivity improvement for detecting colorectal cancer recurrence using circulating tumor DNA. The Oncodetect assay targets low levels of tumor DNA in the bloodstream to support closer monitoring of patients after colorectal surgery. The sensitivity gains for Oncodetect in the Beta-CORRECT study are important, but investors should weigh them...
Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer
23.10.2026 13:15
For patients with colorectal cancer, surgery can remove visible cancer, but it can be difficult to know whether minute traces of the disease remain. Abbott (NYSE: ABT) today announced new Beta-CORRECT data presented at the European Society for Medical Oncology (ESMO) Congress showing that the whole-genome sequencing (WGS)-based Oncodetect® molecular residual disease (MRD) test achieved a 30-percent absolute improvement in sensitivity for colorectal cancer recurrence within two years of surgery,
Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $120
23.10.2026 10:17
Wells Fargo analyst Larry Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $119 to $120.
Abbott's New Beta-CORRECT Data At ESMO Congress Demonstrates 30% Enhancement In Sensitivity For Colorectal Cancer Recurrence Within Two Years Of Surgery
23.10.2026 09:17
Abbott (NYSE:ABT) today announced new Beta-CORRECT data presented at the European Society for Medical Oncology (ESMO) Congress showing that the whole-genome sequencing (WGS)-based Oncodetect® molecular residual disease
Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold Firm
21.10.2026 17:44
Stock Preachers News Commentary - Three sessions into the week, growth and small caps are setting the pace. The Nasdaq Composite jumped 1.04% on the day and is up 2.14% for the week to 26,700.62, while the Russell 2000 added 0.44% to push its weekly gain to 2.36%. The Dow and S&P 500 are contributing too, both up more than 1.2% for the week, as earnings from industrial, healthcare, exchange and homebuilding names give investors fresh data points to sort leaders from laggards. Active Companies fr
What Abbott Laboratories (ABT) Said on Its Q3 Earnings Call
21.10.2026 17:04
Abbott Laboratories (NYSE:ABT) reported third-quarter sales growth of 7% and adjusted earnings-per-share growth of 9%, while announcing plans to separate its nutrition business into an independent publicly traded company through a tax-free distribution to shareholders. Chairman and Chief Executive
Abbott Laboratories Q3 2026 Earnings Call Summary
21.10.2026 16:49
Moby summary of Abbott Laboratories's Q3 2026 earnings call
Abbott plans to spin out its nutrition business
21.10.2026 16:45
Abbott, which also cut its 2026 sales growth guidance, said company sales will total $42 billion following the separation.
Abbott Laboratories plans to spin off nutrition business, following years of tumult over infant formulas
21.10.2026 15:03
Abbott Laboratories plans to spin off its nutrition business into a separate company – a move that follows years of tumult over its infant formulas. The new business will sell Abbott products including Similac, PediaSure, Pedialyte, Glucerna and Ensure. The north suburban-based company also makes medical tests, medical devices and generic pharmaceuticals. The new company is expected to have ...
Abbott Yo-Yoes On 'Choppy' Third Quarter As A Key Spinoff Looms
21.10.2026 14:01
Abbott stock yo-yoed early Wednesday on "choppy" third-quarter metrics and lowered sales growth expectations.
Abbott Plans to Separate Nutrition Business Into Publicly Traded Company by End of 2027
21.10.2026 13:47
Abbott Laboratories (NYSE:ABT) has announced plans to spin off its Nutrition division into a separate publicly traded company, with the transaction expected to be completed by the end of 2027, subject to regulatory and corporate approvals. The proposed separation would create an independent business focused on nutritional products while allowing Abbott to concentrate on its medical devices, diagnostics and established pharmaceuticals operations.
Abbott Stock Falls 4% on Similac Spinoff: It’s Shedding Its Slowest Business, but Who Keeps the Lawsuits?
21.10.2026 13:36
Abbott Laboratories (ABT:NYSE) shares fell more than 4% before the bell on October 21 after the company said it will spin off its Nutrition business, home of Similac, Pedialyte and Ensure, into a separate public company by the end of 2027. The unit brings in about $8.
Abbott to Spin Off Troubled Nutrition Unit to Focus on Growth
21.10.2026 13:17
Abbott Laboratories plans to separate its global nutrition business into an independent, publicly traded company by the end of next year.
Abbott Labs’ (ABT) Solid Financial Beat Signals Long EPS Growth and Dividend Safety
21.10.2026 13:15
Longleaf Partners, managed by Southeastern Asset Management, released its third-quarter 2026 investor letter for its “Partners Fund”. The letter can be downloaded here. Coming into this year, the Fund’s three-year annualized returns were at 11.7%, but recent performance, particularly this year and in Q3, has raised concerns about the investment strategy. The Fund returned 2.41% in […]
Abbott to Carve Out Nutrition Business Into Independent Company
21.10.2026 13:10
Abbott plans to separate its nutrition business into an independent company, which is set to house electrolyte-beverage brand Pedialyte, as well as infant-formula brand Similac, with about $8.5 billion in annual sales.
Abbott Topples After Announcing Plans To Spin Off Its Nutrition Business
21.10.2026 12:55
Abbott stock took a hit Wednesday after the healthcare company said it plans to spin off its nutrition business.
Abbott Laboratories’s (NYSE:ABT) Q3 2026 earnings results: revenue in line with expectations
21.10.2026 12:37
Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q3 2026, with sales up 14.5% year on year to $13.01 billion. Its non-GAAP profit of $1.42 per share was in line with analysts’ consensus estimates.
Abbott (ABT) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
21.10.2026 12:30
Although the revenue and EPS for Abbott (ABT) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ABT Stock Down Post Q3 Earnings Miss, Revenues Rise Y/Y, Margins Up
21.10.2026 12:29
Abbott's Q3 earnings miss weighs on its stock despite double-digit revenue growth and expanding margins, while lower 2026 sales guidance raises concerns.
Abbott Laboratories (NYSE:ABT) Posts In-Line Q3 Results as Reaffirmed Guidance and Nutrition Separation Pressure Shares
21.10.2026 12:21
Abbott Q3 2026 results were in line, with slight revenue and EPS misses, reaffirmed guidance, Nutrition separation plans, and shares down 4.3% premarket.